Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.
Autorzy:
Brodowicz T; Clinical Division of Oncology and Department of Medicine I, Medical University of Vienna and CECOG, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Lang I; Ráth György u. 7-9, National Institute of Oncology, H-1122 Budapest, Hungary. Kahan Z; Department of Oncotherapy, University of Szeged, H-6720 Szeged, Korányi fasor 12, H-6720 Szeged, Hungary. Greil R; IIIrd Medical Department, Paracelsus Medical University Hospital Salzburg and AGMT, Salzburg, Austria. Beslija S; Institute of Oncology, Clinical Center, University of Sarajevo, Bolnicka 27, 71000 Sarajevo, Bosnia and Herzegovina. Stemmer SM; Davidoff Center, Rabin Medical Center, Kaplan Street, Petah Tiqwa 49100, Israel. Kaufman B; Breast Oncology Institute, Sheba Medical Center, 52621 Tel Hashomer, Ramat-Gan, Israel. Petruzelka L; Department of Oncology, First Faculty of Medicine and General Teaching Hospital, Charles University Prague, U Nemocnice 2, 128 08 Prague 2, Czech Republic. Eniu A; Department of Breast Tumors, Cancer Institute Ion Chiricuţă, Republicii 34-36, 400015 Cluj-Napoca, Romania. Anghel R; University of Medicine and Pharmacy Bucharest, Soseaua Fundeni, Nr 252, Sector 2, Bucharest 022328, Romania. Koynov K; Department of Medical Oncology, Hospital Serdika, 6 Damyan Gruev street, 1303 Sofia, Bulgaria. Vrbanec D; Department of Medical Oncology, University Hospital Zagreb-Rebro, Medical University of Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. Pienkowski T; Oncology Department, European Health Centre Otwock, ul. Borowa 14/18, 04-500 Otwock, Poland. Melichar B; Department of Oncology, Palacký University Medical School, I. P. Pavlova 6, 775 20 Olomouc, Czech Republic. Spanik S; St Elisabeth Cancer Institute, Heydukova 10, 812 50 Bratislava, Slovak Republic. Ahlers S; Biometrics, IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany. Messinger D; Biometrics, IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany. Inbar MJ; Oncology Division, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel. Zielinski C; Clinical Division of Oncology and Department of Medicine I, Medical University of Vienna and CECOG, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Nov 25; Vol. 111 (11), pp. 2051-7. Date of Electronic Publication: 2014 Sep 30.
Progesterone receptor status and tumor size as possible indicators of axillary lymph node involvement in T1 carcinoma of the breast.
Autorzy:
Ron IG; Department of Oncology, Tel Aviv-Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Israel. Kovner F Lifschitz-Mercer B Inbar MJ
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
